Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a large decline in short interest in February. As of February 27th, there was short interest totaling 12,975 shares, a decline of 29.3% from the February 12th total of 18,363 shares. Based on an average daily volume of 4,828 shares, the short-interest ratio is presently 2.7 days. Currently, 1.0% of the shares of the stock are sold short. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 4,828 shares, the short-interest ratio is presently 2.7 days.

Institutional Trading of Sonoma Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. McKinley Carter Wealth Services Inc. bought a new position in Sonoma Pharmaceuticals in the 4th quarter worth approximately $41,000. Heron Bay Capital Management bought a new position in Sonoma Pharmaceuticals in the 2nd quarter valued at $96,000. Finally, DRW Securities LLC boosted its position in Sonoma Pharmaceuticals by 257.2% in the 4th quarter. DRW Securities LLC now owns 60,977 shares of the company’s stock valued at $222,000 after buying an additional 43,907 shares during the last quarter. 1.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Stock Performance

Sonoma Pharmaceuticals stock traded up $0.03 on Monday, reaching $2.48. The company’s stock had a trading volume of 4,818 shares, compared to its average volume of 15,051. The business’s fifty day moving average price is $3.06 and its 200 day moving average price is $3.57. The company has a market cap of $4.29 million, a price-to-earnings ratio of -1.22 and a beta of 1.66. Sonoma Pharmaceuticals has a twelve month low of $1.75 and a twelve month high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Tuesday, February 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). The business had revenue of $4.35 million during the quarter, compared to the consensus estimate of $5.47 million. Sonoma Pharmaceuticals had a negative net margin of 19.04% and a negative return on equity of 42.56%. As a group, equities analysts forecast that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.